The National Institute for Health and Care Excellence (NICE) has recommended Janssen's Tremfya as a cost-effective treatment for plaque psoriasis, Pharma Times reported on Friday.
A Final Appraisal Determination was published by the cost regulator to back the funding for the drug, which was launched in the UK in the November.
Tremfya (guselkumab) is the first biologic to selectively target interleukin (IL)-23, a key protein involved in the immune inflammatory response in psoriasis.
The Final Appraisal Determination was fast-tracked as a result of the European approval in November last year. Approval was based on Phase III trials, VOYAGE 1 and VOYAGE 2, which showed high rates of skin clearance.
Janssen has agreed a confidential patient access scheme with the Department of Health and Social Care, offering the drug to the NHS at a reduced cost.
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma